Charles River Laboratories International Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $4B-1.3% YoYTTM through 27 Jun 2026
Net Income -$238.5M-1,174.0% YoYTTM through 27 Jun 2026
Free Cash Flow $370.6MTTM through 27 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 32.9% |
| EBITDA Margin | 9.7% |
| Operating Margin | 0.6% |
| Net Margin | -6.0% |
Returns
-4.6%ROE
-2.0%ROA
-5.0%ROIC
Balance Sheet Health
Debt / Equity0.68x
Current Ratio1.35x
Net Debt$1.9B
Cash & Equivalents$192M
Quality Metrics
Altman Z-Score2.66
Piotroski F-Score4 / 9
FCF Margin9.3%
Earnings-Beat Rate100.0%
Multi-Year Trend
RevenueFY2025: $4B
Diluted EPS-$4.80TTMFY2025: $-2.91
Dividend
No dividend
Capital Allocation
Capex Intensity5.3%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Discovery and Safety Assessment (DSA) | $2.4B | -2.0% | View detailsAnticipates a return to organic revenue growth in the second half of 2026 driven by robust booking trends. |
| Research Models and Services (RMS) | $846.1M | +2.0% | View detailsFocusing on footprint optimization and site consolidation to drive efficiency. |
| Manufacturing Solutions | $766.4M | -0.4% | View detailsDivestiture of CDMO and Cell Solutions businesses expected to streamline segment focus. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.